Sensex: 81,796.15 (-0.33%)

Nifty: 24,858.00 (-0.35%)

anubhai angaldas Securities Pvt. Ltd. Member: BSE - NSE - CDSL

Technology . Transparency . Trust

Contact Us
Apply For IPO

MARKET

Hot Pursuit
Zydus Life subsidiary ZHL appoints Swati Dalal as MD
16-Jun-2025 14:42

The appointment was approved by the nomination and remuneration committee (NRC).

Swati Dalal is part of the senior management team at Zydus Lifesciences and brings extensive leadership experience to her new role as Managing Director of Zydus Healthcare.

Swati Dalal is a seasoned commercial leader with over 30 years of rich and diverse experience in the healthcare and pharmaceutical industry. She began her career with Wockhardt Nutrition before moving to the erstwhile Boots, where she continued through successive mergers with Knoll, Solvay, and Abbott, progressively taking on leadership roles across the organisation.

During her tenure at Abbott, she held various senior positions across both commercial and support functions. These included commercial director ' sales & marketing, as well as leadership of new product introductions (NPI), business development, and commercial excellence. She later served as managing director of Abbott Nutrition and Abbott Primary Care, and most recently, as managing director of Abbott India.

Swati has also been a strong proponent of employee development and inclusion. She has led and contributed to initiatives such as women leaders of Abbott, the early career network, and has actively championed Abbott's diversity, equity, and inclusion (DEI) agenda in India.

Swati holds a pharmacy degree from P.K.M. Kundnani College of Pharmacy, Mumbai and a post-graduate degree in Management Studies from Jamnalal Bajaj Institute of Management Studies in Mumbai.

Swati Dalal is not related to any of the directors of Zydus Lifesciences or its wholly owned subsidiary, Zydus Healthcare.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company's consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24.

Shares of Zydus Lifesciences shed 0.51% to Rs 970 on the BSE.

Powered by Capital Market - Live News

Attention Investor
As per CDSL communiqué Kindly update your Email ID, Mobile Number & Income Range in CDSL demat Account on or before 31st May 2021, Non Compliance Account will be INACTIVE after 31st May 2021. | Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors.  | "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account." | "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."    Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of Investors.